As the leading cause of death by a bacterial infection, tuberculosis (TB) caused 1.5 million deaths in 2020. According to the World Health Organization (WHO), a quarter of the world population is infected with Mycobacterium tuberculosis (Mtb), the cause of TB. The COVID-19 pandemic reduced access to TB diagnosis and treatment, and resulted in an increase in TB deaths in 2020, the first time during the past decade. Thus, there is an urgent need to develop advanced vaccines and drugs against TB infections, which requires a better understanding of the immunology during Mtb infection.
This research topic aims to gather articles that will focus on the innate and adaptive immune responses during Mtb infection, and present the latest progress of novel TB vaccines and immunotherapies. We welcome Original Research, Clinical Trial, Review, Mini-review, Systematic Review, Case Report, and Opinion articles related to the immune mechanism of TB infection and anti-TB immune responses, immune balance between Mtb and the host, and the latest progress of novel TB vaccine and immunotherapy in pre-clinical and clinical studies.
The collection of articles can include, but not limited to, the following subtopics:
(1) Updates on the immune escape of Mtb infection, and innate/adaptive immune responses against Mtb infection.
(2) Host-pathogen cross talk at the local sites of infection.
(3) Novel insights and approaches to TB vaccine and immunotherapy research development in pre-clinical and clinical studies.
(4) Novel approaches to improve the protective efficacy of current TB vaccines.
(5) Novel adjuvants in TB vaccine research development.
(6) Identification of novel markers related to predicting TB vaccine efficacy.
(7) Natural resistance to Mtb infection.
(8) Host-directed prevention/therapy of Mtb infection.
As the leading cause of death by a bacterial infection, tuberculosis (TB) caused 1.5 million deaths in 2020. According to the World Health Organization (WHO), a quarter of the world population is infected with Mycobacterium tuberculosis (Mtb), the cause of TB. The COVID-19 pandemic reduced access to TB diagnosis and treatment, and resulted in an increase in TB deaths in 2020, the first time during the past decade. Thus, there is an urgent need to develop advanced vaccines and drugs against TB infections, which requires a better understanding of the immunology during Mtb infection.
This research topic aims to gather articles that will focus on the innate and adaptive immune responses during Mtb infection, and present the latest progress of novel TB vaccines and immunotherapies. We welcome Original Research, Clinical Trial, Review, Mini-review, Systematic Review, Case Report, and Opinion articles related to the immune mechanism of TB infection and anti-TB immune responses, immune balance between Mtb and the host, and the latest progress of novel TB vaccine and immunotherapy in pre-clinical and clinical studies.
The collection of articles can include, but not limited to, the following subtopics:
(1) Updates on the immune escape of Mtb infection, and innate/adaptive immune responses against Mtb infection.
(2) Host-pathogen cross talk at the local sites of infection.
(3) Novel insights and approaches to TB vaccine and immunotherapy research development in pre-clinical and clinical studies.
(4) Novel approaches to improve the protective efficacy of current TB vaccines.
(5) Novel adjuvants in TB vaccine research development.
(6) Identification of novel markers related to predicting TB vaccine efficacy.
(7) Natural resistance to Mtb infection.
(8) Host-directed prevention/therapy of Mtb infection.
